Multiple Myeloma

>

Latest News

CAR T-cells
Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma

November 4th 2024

An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma.

hand drawing arrows on chalk board
High-Risk Myeloma Treatment Is Not One-Size-Fits-All

October 17th 2024

multiple myeloma on tablet
Talquetamab May Be Underutilized in Relapsed/Refractory Myeloma

October 15th 2024

gloved hand picking up vials of blood
Allogeneic CAR T-Cell Therapy Is Safe, Effective in Heavily Pretreated Myeloma

October 5th 2024

blood vials with cells
Cilta-Cel Continues to Boosts Survival in Pretreated Myeloma

October 3rd 2024

More News

© 2024 MJH Life Sciences

All rights reserved.